Wire · opportunities
FDA approves drug for infantile-onset Niemann-Pick type C after analysis finds longer survival
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 November 2026 · Fusion42 review
The FDA approved the drug cyclodextrin (Adrabetadex) for infantile-onset Niemann-Pick type C after clinical trials demonstrated longer survival in patients. This novel therapy addresses the cellular lipid transport defect caused by mutations in the NPC1 gene and represents two decades of NIH-led foundational research and collaboration with industry.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 17 Nov 2026 and 18 Nov 2026.
◆ ◆ The Wire takeaway
You have a new regulatory blueprint showing that sustained NIH-led research can open rare disease markets previously considered untreatable. This approval widens pathways for startups tackling genetic neurodegenerative conditions.
◆ Coverage
5 sources · first reported 17 Nov 2026 · latest 18 Nov 2026
◆ Related on Wire
◆ Topics